Please select the eligibility criteria that correspond to the clinical trial below.
Title: Effect of a Pharmaceutical Intervention on the Level of Control of the Asthmatic Patient
Brief Summary: Measurement of disease control, treatment adherence and patient knowledge of his/her medication in patients that are receiving a pharmaceutical intervention compared with those patients who receive regular pharmaceutical care.


Options:
A: Inclusion Criteria:

1. Age \>50 years
2. ≥ 4 weeks of pain, aching or discomfort in or around the knee
3. Overweight or obese defined as BMI defined as ≥ 27 kg/m2
4. Not actively participating in a formal exercise program within the past 6 months
5. Self-reported difficulty in at least one of the following activities attributed to knee pain: lifting and carrying groceries, walking one quarter of a mile, getting in and out of a chair, or going up and down stairs.
6. Meet eligibility using the criteria on the pharmacist screening form (see attachment) - This form was adapted from the PhIND-OA study and amended to include points #3 to 6 above.

Exclusion Criteria:

1. Significant co-morbid disease that would pose a safety threat or impair ability to participate in an exercise program
2. Inability or unwillingness to modify dietary or exercise behaviours.
3. Knee X-Ray within the last 2 years
4. Inability to speak and write English
5. Knee pain due only to referred pain from osteoarthritis of the hip
B: Inclusion Criteria:

* Patients who have given their informed consent and expressed interest in participating in the study
* Asthmatic Patients

Exclusion Criteria:

* Patients with communication difficulties.
* Persons who obtain symbicort but not for their own use.
* Patients with other major diseases: Heart problems, COPD, EMPHYSEMA, lung cancer, AIDS.
* Patients with a respiratory infection.
* Patients with seasonal asthma.
* Pregnant women
* Patients who have previously participated in a health education study in asthma.
C: Inclusion Criteria:

* individuals who fill a (incident or prevalent) prescription for inhaled corticosteroids (either monotherapy or in combination inhaler with long-acting beta-agonists) who have been diagnosed by a doctor as having asthma
* possessing a cell-phone with ability to send/receive text messages
* residing in British Columbia (BC), Canada and planning to reside in BC for the next 12 months
* registered with the medical services plan (MSP, the provincial insure of medically-required services) in the past 12 months, and planning to remain registered for the next 12 months
* designated pharmacy being the main drugstore for patient
* not participating in another interventional study
* consent to participate in the study.

Exclusion Criteria:

* Unable to communicate in English
* Under 14 years of age
D: Inclusion Criteria:

* The proposed clinical trial will be conducted in volunteers with Chagas disease complicated by heart failure.
* Subjects will include adults, men and women, racial or ethnic minorities.
* Diagnosed by two distinct Chagas serology tests (indirect immunofluorescence and enzyme linked immunosorbent assay

Exclusion Criteria:

* Patients with any of comorbidities that significantly affect the cardiac performance, such as coronary artery disease, moderate or severe heart valvular disease, left ventricular (LV) hypertrophy, congenital heart disease, or that limit their survival, such as malignant tumors and HIV, will be excluded from the study.
* Patients will be also be excluded in case of failure to give informed consent, inability to perform 6 minute- walk test, significant cognitive impairment, or pregnancy.
* Individuals who are participating in others intervention trials will also be excluded.

Answer: B